SCHEMBL4835148

SCHEMBL4835148

NC1=c2ccoc2=NCN1c1ccc(NS(=O)(=O)c2cccc3ccccc23)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.44
▸ PGR P06401 1/20 0.44
▸ SGK1 O00141 1/20 0.42
▸ HDAC1 Q13547 2/20 0.42
▸ PTPN2 P17706 1/20 0.42
▸ PTPN1 P18031 1/20 0.42
▸ PTPN5 P54829 1/20 0.42
▸ RORA P35398 1/20 0.41
▸ RORC P51449 1/20 0.41
▸ NR1H2 P55055 1/20 0.41
▸ NR1H4 Q96RI1 1/20 0.41
▸ GHSR Q92847 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ PFKFB3 Q16875 1/20 0.39
▸ TYMS P04818 1/20 0.38
▸ HTR6 P50406 6/20 0.38
▸ NR1I2 O75469 1/20 0.38
▸ EDNRB P24530 1/20 0.38
▸ EDNRA P25101 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4830890 0.90 PKLR (0.42) SGK1
SCHEMBL4833826 0.89 HTR6 (0.41) TSHRSGK1ALDH1A1HTR6EDNRA
SCHEMBL4831112 0.88 NPY5R (0.38) SGK1PTPN2PTPN1PTPN5GHSR
SCHEMBL4825823 0.86 PGR (0.42) PGRSGK1HDAC1PTPN2PTPN1
SCHEMBL4834414 0.86 GFER (0.55) HDAC1ALDH1A1HTT
SCHEMBL4833658 0.84 PGR (0.43) PGRSGK1GHSRALDH1A1
SCHEMBL4833946 0.83 KEAP1 (0.46) PGRALDH1A1HTR6NR1I2
SCHEMBL4826272 0.83 KMT2A (0.53) PTPN2PTPN1PTPN5ALDH1A1HTT
SCHEMBL4834620 0.83 HSD11B1 (0.43) SGK1HTR6EDNRBEDNRA
SCHEMBL4836961 0.81 ALDH1A1 (0.52) TSHRPTPN2PTPN1PTPN5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US claimed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP claimed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK TSHR 3073/4885PGR 1159/4885SGK1 2615/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR TSHR 3243/4885PGR 1480/4885SGK1 4345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback